Literature DB >> 29869728

Binding of indomethacin methyl ester to cyclooxygenase-2. A computational study.

Menyhárt-Botond Sárosi1.   

Abstract

Inhibitors selective towards the second isoform of prostaglandin synthase (cyclooxygenase, COX-2) are promising nonsteroidal anti-inflammatory drugs and antitumor medications. Methylation of the carboxylate group in the relatively nonselective COX inhibitor indomethacin confers significant COX-2 selectivity. Several other modifications converting indomethacin into a COX-2 selective inhibitor have been reported. Earlier experimental and computational studies on neutral indomethacin derivatives suggest that the methyl ester derivative likely binds to COX-2 with a similar binding mode as that observed for the parent indomethacin. However, docking studies followed by molecular dynamics simulations revealed two possible binding modes in COX-2 for indomethacin methyl ester, which differs from the experimental binding mode found for indomethacin. Both alternative binding modes might explain the observed COX-2 selectivity of indomethacin methyl ester. Graphical abstract Binding of indomethacin methyl ester to cyclooxygenase-2.

Entities:  

Keywords:  Cyclooxygenase; Docking simulations; Indomethacin derivatives; Molecular dynamics; Protein-ligand binding

Mesh:

Substances:

Year:  2018        PMID: 29869728     DOI: 10.1007/s00894-018-3686-8

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  33 in total

1.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald.

Authors:  Romelia Salomon-Ferrer; Andreas W Götz; Duncan Poole; Scott Le Grand; Ross C Walker
Journal:  J Chem Theory Comput       Date:  2013-08-20       Impact factor: 6.006

2.  Stereoselective binding of indomethacin ethanolamide derivatives to cyclooxygenase-1.

Authors:  Christopher W Moth; Jeffrey J Prusakiewicz; Larry J Marnett; Terry P Lybrand
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

3.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

4.  Profiling indomethacin impurities using high-performance liquid chromatography and nuclear magnetic resonance.

Authors:  S Hess; U Teubert; J Ortwein; K Eger
Journal:  Eur J Pharm Sci       Date:  2001-12       Impact factor: 4.384

5.  Kinetic basis for selective inhibition of cyclo-oxygenases.

Authors:  J K Gierse; C M Koboldt; M C Walker; K Seibert; P C Isakson
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

6.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.

Authors:  R G Kurumbail; A M Stevens; J K Gierse; J J McDonald; R A Stegeman; J Y Pak; D Gildehaus; J M Miyashiro; T D Penning; K Seibert; P C Isakson; W C Stallings
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

7.  Enantiospecific, selective cyclooxygenase-2 inhibitors.

Authors:  Kevin R Kozak; Jeffery J Prusakiewicz; Scott W Rowlinson; Lawrence J Marnett
Journal:  Bioorg Med Chem Lett       Date:  2002-05-06       Impact factor: 2.823

8.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

Review 9.  Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond.

Authors:  Shu Xu; Carol A Rouzer; Lawrence J Marnett
Journal:  IUBMB Life       Date:  2014-12-23       Impact factor: 3.885

10.  Conservative Secondary Shell Substitution In Cyclooxygenase-2 Reduces Inhibition by Indomethacin Amides and Esters via Altered Enzyme Dynamics.

Authors:  Mary E Konkle; Anna L Blobaum; Christopher W Moth; Jeffery J Prusakiewicz; Shu Xu; Kebreab Ghebreselasie; Dapo Akingbade; Aaron T Jacobs; Carol A Rouzer; Terry P Lybrand; Lawrence J Marnett
Journal:  Biochemistry       Date:  2015-12-31       Impact factor: 3.162

View more
  1 in total

Review 1.  Pt(IV) Prodrugs with NSAIDs as Axial Ligands.

Authors:  Daniil Spector; Olga Krasnovskaya; Kirill Pavlov; Alexander Erofeev; Peter Gorelkin; Elena Beloglazkina; Alexander Majouga
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.